SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as retail investors draw comparisons to the 2021 short squeeze, with some hoping it will mirror the recent volatility in $BYND. Community members discuss call options, potential buybacks, and the possibility of a gamma squeeze. Despite the positive price action, some remain skeptical, citing weak fundamentals and high volatility.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer's stock is trending due to a revised revenue outlook, citing design win upgrades impacting delivery schedules and shifting some revenue to the next quarter. Despite reiterating a strong fiscal year forecast, the community is actively debating the impact of the news, management's credibility, and potential trading strategies given the volatility. Some investors express frustration with the company's leadership and consistency in meeting expectations, while others view the dip as a buying opportunity amidst robust AI demand.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is trending as it joins the S&P 100, sparking community discussion about the company finally breaking the $100 mark. Bullish sentiment is fueled by strong financials, autonomous vehicle developments, and a potential for further gains, although some traders express frustration with past price action. Many are closely watching if Uber can maintain momentum and solidify its position.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending as investors anticipate the upcoming GTC conference, where new products and partnerships are expected to be revealed, possibly driving the stock toward $190. Bullish sentiment is fueled by optimism surrounding potential deals and positive economic data, while some traders are wary of potential pullbacks and China-related headwinds. The community is actively discussing potential price movements and technical analysis, with strong opinions on both bullish and bearish scenarios.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies is trending as investors discuss its strategic partnership with Palantir to enhance enterprise AI capabilities and its potential role in the growing AI sector, particularly regarding data centers and fiber optic infrastructure. Community members are also anticipating upcoming earnings and speculating on potential acquisitions. The broader discussion revolves around Lumen's transformation and its position in the evolving tech landscape.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum ($QBTS) is trending amid speculation that the Trump administration might take an equity stake in quantum computing firms, fueling significant community discussion and trading volume. Despite some contradictory reports and denials of ongoing negotiations, chatter persists around the potential for government investment to boost the sector and counter China's quantum initiatives. Traders are actively debating the validity of news sources and the potential impact on the stock's future.

Ventyx Biosciences, Inc. engages in developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded by Raju S. Mohan on November 21, 2018 and is headquartered in San Diego, CA.

Ventyx Biosciences Inc

Ventyx Biosciences is trending following positive Phase 2 trial results for its Parkinson's drug, showing safety and target engagement. The community is buzzing about potential analyst upgrades and buyout scenarios, particularly by Sanofi given their existing relationship. Discussions also involve the drug's broader applicability and market potential beyond Parkinson's.

Bleichroeder Acquisition Corp. I is a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Andrew Stephen Gundlach and Michel Combes on June 24, 2024 and is headquartered in New York, NY.

Bleichroeder Acquisition Corp. I - Ordinary Shares - Class A

Bleichroeder Acquisition Corp I

Bleichroeder Acquisition Corp I (BACQ) is trending due to increased interest following bullish sentiment from Citron Research, highlighting the company's merger with Merlin Labs, an AI autonomous flight technology firm, and existing government contracts. The community is actively discussing the potential for significant gains, particularly focusing on the undervalued rights and the company's partnerships within the aerospace and defense sectors. Some are drawing comparisons to other AI-related SPACs and anticipating a substantial price increase.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is trending amid news of a partnership with Anthropic to integrate AI models into its software, seen as a boost to enterprise AI capabilities. The community is discussing IBM's leadership in quantum computing and AI, as well as its potential for long-term growth, though some remain cautious. Recent analyst ratings and price target adjustments are also contributing to the conversation around the stock.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is trending amid speculation surrounding a potential sale or strategic partnership, possibly involving major players like SpaceX or Amazon, following comments from the chairman about a potential multi-billion dollar deal. Community discussions revolve around the valuation of Globalstar's spectrum and assets, comparing it to recent transactions in the satellite communications sector, and the potential impact of Apple's involvement and the company's expansion in IoT.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

COMPASS Pathways (CMPS) Upgraded to Buy: Here's Why

COMPASS Pathways (CMPS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Stifel said the plunge in Compass Pathways shares was “significantly overdone” after data showed that the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/compass-pathways-stock-slumps-after-positive-late-stage-trial-results-from-psychedelic-drug-underwhelm-analysts/chm59LwRRdc">company’s COMP360</a> met the primary endpoint in a Phase 3 trial for treatment-resistant depression.Compass Pathways shares plunged 49.2% to close at $2.35 on Monday before recovering 7.2% to $2.52 in after-hours trading.While the 3.6-point difference on the Montgomery-Åsberg depression rating scale (MADRS) was “a little lighter than expected,” the firm noted the results were “clearly positive” from a regulatory perspective.Stifel added that the effect size was “pretty good” for a treatment-resistant population and argued that in neuropsychiatry, commercial success is not always determined by effect size alone.&nbsp;The firm maintained a ‘Buy’ rating on the stock and a $11 price target.On Monday, Compass said that a single 25 mg dose of COMP360 meaningfully and statistically significantly reduced depression symptoms vs. placebo at week 6.The p-value was less than 0.001, meaning there was less than a 0.1% chance the result was due to chance.Compass Pathways is also conducting a second Phase 3 study evaluating the effects of two doses of COMP360 given three weeks apart.&nbsp;A second late-stage study, COMP006, is ongoing and will assess the effect of two fixed doses, which will be given three weeks apart.&nbsp;The company plans to discuss the results with the U.S. Food and Drug Administration.Following the trial update, Evercore ISI downgraded Compass to 'In Line' from 'Outperform' and cut its price target to $6 from $11, calling the 3.6-point symptom reduction "underwhelming" and citing questions around the drug's long-term durability.Meanwhile, H.C. Wainwright maintained a 'Buy' rating and $45 target, calling the results "a historic first for psychedelic therapy" and viewing COMP360 as a potential first-in-class option in a large, underserved market.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 7,567% surge in 24-hour message volume.One user said they were still holding Compass Pathways shares despite disappointment over the more than 50% drop following positive trial results, noting that the after-hours price action provided some relief.<stembedurl>https://stocktwits.com/WMWilson/message/618751654</stembedurl>Another user pointed out that a similarly weak initial reaction had occurred with Sagimet Biosciences after its Phase 3 data, but the stock recovered.<stembedurl>https://stocktwits.com/LoonaManStan/message/618762972</stembedurl>The stock has declined 43.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stifel Says Compass Pathways Selloff 'Significantly Overdone' After Psilocybin Trial Data

The company is also conducting a second Phase 3 study evaluating the effects of two doses of COMP360 given three weeks apart. 

Equity

Shares of Compass Pathways Plc. (CMPS) slumped 47% on Monday afternoon after the <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.compasspathways.com/News--Events-/news/news-details/2025/Compass-Pathways-Successfully-Achieves-Primary-Endpoint-in-First-Phase-3-Trial-Evaluating-COMP360-Psilocybin-for-Treatment-Resistant-Depression/default.aspx">results</a> from the late-stage trials of COMP360 in treatment-resistant depression fell short of market expectations.COMP360 is a synthetic, proprietary formulation of psilocybin. Psilocybin is part of a group of drugs called psychedelics or hallucinogens with the ability to alter one’s sense of perception.Compass Pathways said that a single dose of the drug reduced symptom severity by 3.6 points from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) as compared to placebo at week 6.The company said it will discuss the “highly statistically significant and clinically meaningful” data with the U.S. Food and Drug Administration, which has yet to review it.The company is also running another late-stage trial for the drug, which aims to evaluate the efficacy of two fixed doses taken three weeks apart.According to Compass Pathways, an estimated 21 million adults in the U.S. suffer from major depression, and approximately 9 million are drug-treated.Approximately a third of patients with major depressive disorder will develop treatment-resistant depression, which is defined as an inadequate response to two or more appropriate courses of approved medications.Following the announcement, Evercore ISI downgraded Compass Pathways to ‘In Line’ from ‘Outperform’ with a price target of $6, down from $11.The reduction in symptom severity by 3.6 points as compared to placebo on a standardized depression scale "underwhelmed," the analyst told investors, as per TheFly.This dataset does indicate Compass may have an approvable drug, but the firm noted that durability is a key component for commercial success, and this will remain a question with relatively unclear durability in a mid-stage trial and a weaker effect at 6 weeks in the late-stage trial.H.C. Wainright, however, is more optimistic and noted that the results from the late-stage study mark "a historic first for a psychedelic therapy." The data also positions COMP360 as "a potential first-in-class treatment in a large, underserved depression market," said the analyst, who reiterated a ‘Buy’ rating and $45 price target on the shares.On Stocktwits, retail sentiment around CMPS jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:631/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_23_at_12_27_47_PM_png_d7e1356560.webp" alt="CMPS's Sentiment Meter and Message Volume as of 12:25 p.m. ET on June 23, 2025 | Source: Stocktwits" width="631" height="60"><figcaption>CMPS's Sentiment Meter and Message Volume as of 12:25 p.m. ET on June 23, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that while the late-stage results were good, the market wants ‘groundbreaking’ results.<stembedurl>https://stocktwits.com/aaronmag13/message/618680560</stembedurl><a href="https://stocktwits.com/symbol/CMPS">CMPS stock</a> is down by about 35% this year and nearly 61% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/rezolve-ai-to-be-added-to-russell-indices-after-revenue-surge/chm57C7RRdR">Rezolve Ai To Be Added To Russell Indices After Revenue Surge: Retail Echoes Confidence</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Compass Pathways Stock Slumps After Positive Late-Stage Trial Results From Psychedelic Drug ‘Underwhelm’ Analysts

The company said it will discuss the “highly statistically significant and clinically meaningful” data with the U.S. Food and Drug Administration, which has yet to review it.

Exxon Mobil, Chevron rise premarket; Compass Pathways dips

Investing.com - U.S. stock index futures were hovering around the flatline on Monday, as investors took some caution as they gauged the fallout from weekend U.S. strikes on Iranian nuclear facilities.

COMPASS Pathways (CMPS) Upgraded to Buy: Here's What You Should Know

Shares of Mind Medicine Inc. climbed 3.6% on Thursday and extended gains after hours, with retail sentiment improving following the company's fourth-quarter earnings report.The psychedelics treatment developer reported a net loss of $34.7 million for the quarter ended Dec. 31, 2024, widening from a $23.8 million loss a year earlier, largely due to higher research and development costs tied to its MM120 and MM402 programs.&nbsp;MM120, MindMed's lead drug candidate, is designed to treat generalized anxiety disorder (GAD), while MM402 is being developed to address core symptoms of Autism Spectrum Disorder (ASD).However, the company's adjusted Q4 loss per share of $0.41 narrowed from $0.59 a year ago, though it missed analyst expectations of a $0.28 loss.CEO Rob Barrow remained upbeat, stating that 2024 was a "year of significant progress" and that the company had achieved key milestones leading into multiple Phase 3 clinical readouts for MM120, which he expects to drive MindMed's next growth phase.On Stocktwits, sentiment for MNMD shifted from 'bearish' to 'neutral' in the 24 hours leading up to Thursday, with message volume surging 250%.<figure class="image"><img style="aspect-ratio:1316/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/MNMD_sentiment_and_message_volume_as_of_March_6_8b8a5ebcbf.png" alt="MNMD sentiment and message volume as of March 6.png" width="1316" height="302"><figcaption>MNMD sentiment and message volume as of March 6 | source: Stocktwits</figcaption></figure>One user expressed confidence in MM120's potential, saying, "Once Phase 3 [of the MM120 study] passes, this is going to blow up."<stembedurl>https://stocktwits.com/Bball4/message/606995440</stembedurl>Another key factor boosting optimism was MindMed's strong cash reserves. The company ended 2024 with $273.7 million in cash and cash equivalents, up from $99.7 million a year earlier, which the company expects to be sufficient to support operations into 2027.One user wrote, "We won't have to do any more reverse splits. MNMD has cash reserves until approvals."<stembedurl>https://stocktwits.com/BullsVSBearsVSYoMomma/message/607108323</stembedurl>Additionally, traders pointed to potential government&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mnmd-stock-soars-after-rfk-jr-confirmed-as-hhs-chief/ch5iJvpRH6">support</a> under new Health and Human Services chief Robert F. Kennedy Jr., who has previously advocated for the decriminalization of psychedelics for therapeutic use.The company also plans regulatory and pre-commercialization activities for MM120's orally disintegrating tablet (ODT) version.One watcher pointed out that although MNMD lags behind competitor Compass Pathways in clinical progress, its broader drug pipeline gives it an edge.Mind Medicine shares remain down over 7% year-to-date but have gained over 10% in the past 12 months.&nbsp;According to Koyfin, of the 11 analysts covering the stock, seven rate it a 'buy,' while four have a 'strong buy' rating.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mind Medicine's Net Losses Swell In Q4, But Retail Finds At Least 3 Reasons To Stay Bullish

The psychedelics treatment developer reported a net loss of $34.7 million for the quarter ended Dec. 31, 2024, widening from a $23.8 million loss a year earlier.

Compass Pathways to Participate in TD Cowen 45th Annual Health Care Conference

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at...

Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial...

Shares of Mind Medicine Inc. (MNMD) surged more than 15% Friday afternoon, on track for their best session since April 2024, as retail traders cheered Robert F. Kennedy Jr.’s confirmation as U.S. Health and Human Services secretary.The stock is now set to post weekly gains of over 22%, its strongest performance since the week of Donald Trump’s 2024 election victory in November.&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/MNMD_sentiment_Feb_14_dada4484f8.png" alt="MNMD sentiment Feb 14.png" width="1318" height="324"><figcaption>MNMD sentiment Feb 14 as of 2:30 pm ET | source: Stocktwits</figcaption></figure>On Stocktwits, sentiment turned even more bullish, with message volume skyrocketing 720% in the past three months amid RFK Jr.’s rise to the cabinet.“The RFK bump,” one user wrote, echoing several other posts, while another predicted a “big breakout” next week.&nbsp;<stembedurl>https://stocktwits.com/mpferd/message/604362153</stembedurl><stembedurl>https://stocktwits.com/Knot2/message/604306853</stembedurl>Kennedy has previously&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/livecoverage/trump-cabinet-confirmation-hearings/card/what-has-rfk-jr-said-about-weight-loss-drugs-antidepressants-and-psychedelics--eAaDAxA6vQaSVMeBPlEs">advocated</a> for decriminalizing psychedelics for therapeutic use, citing his son’s positive experience with the hallucinogenic brew ayahuasca.Wall Street has also taken notice.&nbsp;Earlier this month, Chardan named Mind Medicine as a top biotech pick for 2025, citing strong Phase 2 results for its lead drug candidate MM120, which targets generalized anxiety disorder (GAD).&nbsp;The research firm has a ‘Buy’ rating with a $20 price target — implying a doubling from current levels — and projects potential MM120 peak sales of over $1 billion by 2026.In January, Evercore ISI <a href="https://stocktwits.com/news-articles/markets/equity/mnmd-stock-rises-on-evercore-isi-rating/chbVQU4RYM">initiated</a> coverage with an ‘Outperform’ rating and a $23 target, highlighting Mind Medicine’s innovative oral LSD formulation and its potential in treating both GAD and major depressive disorder (MDD).Still, not everyone’s betting on more gains. Short interest has climbed from 12.9% at the start of the year to 14.2% by January’s end, per Koyfin data.<a href="https://stocktwits.com/symbol/MNMD">Mind Medicine shares</a> have gained over 42% year-to-date, outperforming Compass Pathways but lagging Atai Life Sciences’ 79% surge. Those two companies are also developing psychedelic therapeutics.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Robert F. Kennedy Jr. speaks after being sworn in as Secretary of Health and Human Services in the Oval Office at the White House on February 13, 2025 in Washington, DC. (Photo by Andrew Harnik/Getty Images)

Mind Medicine Getting An 'RFK Bump'? Retail Gets More Bullish As Stock Heads For Best Day In Over 10 Months

Kennedy has previously advocated for decriminalizing psychedelics for therapeutic use, citing his son’s positive experience with the hallucinogenic brew ayahuasca.

Compass Pathways to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

CMPS
COMPASS Pathways

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CMPS News

CMPSCOMPASS Pathways